Aisthesis Medical Secures $1.2M for AI Sepsis Prediction Platform
Aisthesis Medical has announced the successful closing of a $1.2 million pre-seed funding round. The funding, led by Twin Path Ventures with participation from TECS Capital, will be used to accelerate the development and regulatory clearance of VIOSync SPI, an AI-powered clinical decision support platform.
VIOSync SPI is designed to predict the onset of sepsis within the next 48 hours by securely ingesting multimodal patient data from hospital systems. This platform aims to provide clinicians with actionable insights to intervene earlier and potentially save lives. The investment will support the advancement of CE MDR submission for VIOSync SPI and expand clinical validation studies across leading hospitals in the UK and EU.
The funding will also enable Aisthesis Medical to strengthen its team and prepare for NHS and international pilot deployments, furthering its mission to empower clinicians with trusted AI tools for preventing life-threatening conditions.
We hope you enjoyed this article.
Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from: Funding
More from: Life Sciences
Subscribe to AI Funding Brief
Whitepaper
Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation
The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.
Read more